hVIVO #HVO – CEO & CFO Share Purchases December 15, 2025 – Posted in: Blog, hVIVO (HVO) – Tags: , , ,

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on 15 December 2025, Yamin ‘Mo’ Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below:

Director

Number of ordinary shares purchased

Purchase price

Resultant holding

Resultant holding as a % of the issued share capital

Yamin ‘Mo’ Khan

3,310,405

6.04p

8,322,008

1.21%

Stephen Pinkerton

520,000

5.5p

1,270,596*

0.19%

*343,232 of these shares were purchased/are held by Mrs Dolores Pinkerton, wife of Stephen Pinkerton

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (“MAR”) EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service (“RIS”), this inside information is now considered to be in the public domain. 

For further information please contact:

hVIVO plc

+44 (0)20 7756 1300

Yamin ‘Mo’ Khan, Chief Executive Officer

Stephen Pinkerton, Chief Financial Officer

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

+44 (0)20 7220 0500

Geoff Nash, Callum Davidson
Trisyia Jamaludin, Harriet Ward

Nigel Birks – Life Science Specialist Sales

Louise Talbot – Sales

Peel Hunt LLP (Joint Broker)

+44 (0)20 7418 8900

James Steel, Dr Christopher Golden

Davy (Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell, Niall Gilchrist

ICR Healthcare (Financial PR & IR)

Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

hVIVO@icrhealthcare.com